{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:44:56Z","timestamp":1761518696739},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,8]]},"DOI":"10.1093\/annonc\/mdf222","type":"journal-article","created":{"date-parts":[[2002,9,30]],"date-time":"2002-09-30T14:40:11Z","timestamp":1033396811000},"page":"1225-1235","source":"Crossref","is-referenced-by-count":32,"title":["A randomized phase II study of sequential docetaxel and doxorubicin\/cyclophosphamide in patients with metastatic breast cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"E.A.","family":"Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Geeraerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Maihle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Kuross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Lafky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf222_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdf222_bb0015","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0140-6736(99)01909-1","article-title":"Trends in mortality from cancer in the European Union, 1955\u201394","volume":"354","author":"Levi","year":"1999","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf222_bb0020","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM199511303332202","article-title":"Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials","volume":"333","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdf222_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(92)90997-H","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf222_bb0030","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf222_bb0035","first-page":"17","article-title":"Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings","volume":"26","author":"Aapro","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1993.146","article-title":"Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type schedules","volume":"67","author":"A\u2019Hern","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf222_bb0045","first-page":"5","article-title":"A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer","volume":"26","author":"Crown","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","article-title":"Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.annonc.a010544","article-title":"A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC","volume":"7","author":"Fumoleau","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.1996.14.1.58","article-title":"Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer","volume":"14","author":"Hudis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0065","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.1996.14.2.422","article-title":"Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Trudeau","year":"1996","journal-title":"J Clin Oncol"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf222_bb0070","first-page":"17","article-title":"Docetaxel versus methotrexate\/5-fluorouracil in patients with advance anthracycline resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group","volume":"111","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf222_bb0075","first-page":"50","article-title":"Phase III study: Docetaxel versus 5-fluorouracil + navelbine in patients with metastatic breast cancer as 2nd line chemotherapy","volume":"223","author":"Bonneterre","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf222_bb0080","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0085","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0090","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","article-title":"Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer","volume":"13","author":"Valero","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0095","first-page":"17","article-title":"Docetaxel in combination with doxorubicin: a phase I dose-finding study","volume":"11","author":"Dieras","year":"1997","journal-title":"Oncology"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf222_bb0100","first-page":"50","article-title":"Phase II study of docetaxel in combination with doxorubicin as first-line chemotherapy of metastatic breast cancer","volume":"262","author":"Dieras","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf222_bb0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0110","first-page":"127a","article-title":"A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC","volume":"18","author":"Nabholtz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf222_bb0115","first-page":"35","article-title":"A phase II randomized study of doxorubicin (A) alternated to docetaxel (T) (ALT) vs sequential administration of 4CY of T followed by 4CY of A (SEQ) as 1st line CT in MBC pts","volume":"1259","author":"Paridaens","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf222_bb0120","first-page":"50","article-title":"Final results of a phase II study of docetaxel, doxorubicin and cyclophosphamide (TAC) as 1st-line chemotherapy in metastatic breast cancer patients","volume":"227","author":"Nabholtz","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf222_bb0125","series-title":"Tyrosine kinases and signal transduction in mouse mammary tumorigenesis","first-page":"397","article-title":"Hormones and Growth Factors in Development and Neoplasia","author":"Siegel","year":"1998"},{"key":"10.1093\/annonc\/mdf222_bb0130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.bi.62.070193.002321","article-title":"Signaling by receptor tyrosine kinases","volume":"62","author":"Fantl","year":"1993","journal-title":"Annu Rev Biochem"},{"key":"10.1093\/annonc\/mdf222_bb0135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/bies.950151207","article-title":"Neu and its ligands: from an oncogene to neural factors","volume":"15","author":"Peles","year":"1993","journal-title":"Bioessays"},{"key":"10.1093\/annonc\/mdf222_bb0140","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/jcp.38.11.1225","article-title":"Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer","volume":"38","author":"Sainsbury","year":"1985","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdf222_bb0145","first-page":"1398","article-title":"Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer","volume":"1","author":"Sainsbury","year":"1987","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf222_bb0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1093\/annonc\/mdf222_bb0155","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/mdf222_bb0160","series-title":"Molecular Diagnostics of Human Cancer: Cancer Cells","first-page":"353","article-title":"Epidermal growth factor receptor: A marker of early relapse in breast cancer and tumor stage progression in bladder cancer; interactions with neu","author":"Harris","year":"1989"},{"key":"10.1093\/annonc\/mdf222_bb0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01806813","article-title":"Prognostic significance of serum c-erbB-2 protein in breast cancer patients","volume":"40","author":"Willsher","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf222_bb0170","first-page":"769","article-title":"EGF-R expression in ductal breast cancer: proliferation and prognostic implications","volume":"17","author":"Bucci","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf222_bb0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3000281","article-title":"Soluble receptors for cytokines and growth factors: generation and biological function","volume":"300","author":"Rose-John","year":"1994","journal-title":"Biochem J"},{"key":"10.1093\/annonc\/mdf222_bb0180","first-page":"193","article-title":"Diagnostic utility of oncogenes and their products in human cancer","volume":"1072","author":"McKenzie","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1093\/annonc\/mdf222_bb0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0027-5107(95)00146-8","article-title":"The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies","volume":"333","author":"Brandt-Rauf","year":"1995","journal-title":"Mutat Res"},{"key":"10.1093\/annonc\/mdf222_bb0190","first-page":"26","article-title":"Soluble epidermal growth factor receptor (EGFr) and neu gene product in voided urine specimens collected from bladder cancer patients","volume":"36","author":"Marley","year":"1995","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdf222_bb0195","series-title":"Stack MS, Fishman DA","first-page":"247","article-title":"EGF\/ErbB family receptors in ovarian cancer","author":"Maihle","year":"2002"},{"key":"10.1093\/annonc\/mdf222_bb0200","first-page":"129","article-title":"Serum SErbB1 and EGF levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer","volume":"8","author":"Baron","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdf222_bb0205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1349-7006.1990.tb02596.x","article-title":"In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells","volume":"81","author":"Mori","year":"1990","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdf222_bb0210","first-page":"53","article-title":"Detection and quantitation of the human neu oncoprotein","volume":"6","author":"Carney","year":"1991","journal-title":"J Tumor Marker Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0215","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1200\/JCO.1992.10.9.1436","article-title":"Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients","volume":"10","author":"Leitzel","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF01212719","article-title":"Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients","volume":"119","author":"Kynast","year":"1993","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcla.1860070107","article-title":"Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers","volume":"7","author":"Wu","year":"1993","journal-title":"J Clin Lab Anal"},{"key":"10.1093\/annonc\/mdf222_bb0230","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF01247465","article-title":"Elevated serum levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy","volume":"129","author":"Meden","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0235","first-page":"757","article-title":"Prognostic significance of p105 (c-erbB-2, HER2\/neu) serum levels in patients with ovarian cancer","volume":"17","author":"Meden","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf222_bb0240","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/bjc.1992.22","article-title":"Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer","volume":"65","author":"Wright","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf222_bb0245","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.1995.13.5.1129","article-title":"Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer","volume":"13","author":"Leitzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0250","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.1997.15.7.2518","article-title":"Prediction of response to antiestrogen therapy in advanced breast cancer patients by pre-treatment circulating levels of extracellular domain of the HER-2\/c-neu protein","volume":"15","author":"Yamauchi","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1005700812422","article-title":"Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients","volume":"43","author":"Fehm","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf222_bb0260","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO.1998.16.7.2409","article-title":"Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy","volume":"16","author":"Mehta","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0265","first-page":"126a","article-title":"Final results of a sequential (SEQ) administration of docetaxel (D) followed by AC as 1st line CT for MBC","volume":"17","author":"Antoine","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdf222_bb0270","first-page":"12","article-title":"Randomized trial of two sequential and one alternating schedules of Taxotere (T)\/FEC 75 in patients with metastatic breast cancer (MBC) as first-line chemotherapy","volume":"9","author":"Spielmann","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0275","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.1999.17.3.862","article-title":"Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer","volume":"17","author":"Kouroussis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0280","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1023\/A:1026437731354","article-title":"Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer","volume":"10","author":"Pagani","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf222_bb0285","first-page":"145","article-title":"Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases","volume":"4","author":"Lacroix","year":"1989","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdf222_bb0290","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4","article-title":"Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer","volume":"73","author":"Isola","year":"1994","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf222_bb0295","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdf222_bb0300","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000227606","article-title":"Tissue expression and serum levels of HER-2\/neu in patients with breast cancer","volume":"54","author":"Krainer","year":"1997","journal-title":"Oncology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419638408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419638408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/8\/1225\/334235\/mdf222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:35:45Z","timestamp":1582166145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419638408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["S0923753419638408"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf222","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}